MK-677 vs Ipamorelin vs CJC-1295
Ghrelin Receptor Agonist (GH Secretagogue) · Growth Hormone-Releasing Peptide (GHRP) · GHRH Analog
Here is how these two compounds compare, based on published research, not marketing claims.
MK-677
The oral GH secretagogue; activates the ghrelin receptor in pill form with metabolic trade-offs (appetite increase, potential glucose effects).
Ipamorelin
The most selective GH secretagogue documented; triggers GH release without raising cortisol, prolactin, or appetite. Injectable.
CJC-1295
A GHRH analog that sustains GH release for days rather than minutes; the DAC modification allows weekly rather than daily dosing.
MK-677
134 studies
24 human trials
Not FDA-Approved
Ipamorelin
48 studies
3 human trials
Not FDA-Approved
CJC-1295
27 studies
2 human trials
Not FDA-Approved
What it does
MK-677
Delivers growth hormone signaling through a pill rather than an injection: the only secretagogue in this class with practical oral bioavailability. Hits the same ghrelin receptor as the injectable compounds, but in a form the gut can absorb. Clinical trials (most notably Murphy et al. and Nass et al.) documented sustained nightly growth hormone and IGF-1 elevation across the 24-hour cycle, alongside the appetite increase and changes in blood sugar handling that ultimately contributed to the failed Alzheimer's trials and the compound's research-only status today.
Ipamorelin
Releases growth hormone without the cortisol or prolactin spike that older ghrelin agonists produced. The most receptor-selective compound in the GH secretagogue class for GHS-R1a, the ghrelin receptor itself. Comparable growth hormone elevation to GHRP-2 or GHRP-6 in head-to-head studies, without the hormonal collateral that made those compounds harder to study.
CJC-1295
Stretches a growth hormone signal that normally lasts minutes into one that lasts days. A small chemistry change attaches the molecule to albumin, a protein already circulating in the blood, which protects it from being broken down. In the published research, that translates to a half-life of roughly six to eight days, compared with minutes for the body's native GHRH.
How it works
MK-677
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland and stimulates growth hormone release. The mechanism is functionally identical to injectable GH secretagogues like ipamorelin and GHRP-6, but the molecule is engineered for oral bioavailability. The body responds to the GH-releasing signal whether the trigger arrives by injection or by mouth. The downstream effect is increased GH followed by increased IGF-1 production from the liver.
Ipamorelin
Ipamorelin acts on a single receptor on the pituitary gland (the ghrelin receptor, GHS-R1a) and triggers growth hormone release without touching the cortisol axis, the prolactin axis, or the appetite signal that older compounds in this class also activated. Other GH secretagogues like GHRP-6 and hexarelin raise cortisol alongside GH, raise prolactin, and sharpen hunger. Ipamorelin does not.
CJC-1295
A modified version of the body's natural growth hormone signal. The modification makes it resist breakdown, so it stays active longer in the bloodstream.
How often
MK-677
Oral administration in research protocols. Published studies use daily oral dosing over periods ranging from 8 weeks to 24 weeks. MK-677 is not FDA-approved for any therapeutic indication; no approved product contains ibutamoren mesylate.
Ipamorelin
In published human pharmacokinetic studies (Johansen 1999), ipamorelin was given as a subcutaneous injection with dose-dependent GH response measured over hours. The Beck 2014 Phase II post-surgical trial used repeated dosing over days. Clinical protocols typically use daily subcutaneous injection, though this frequency derives from clinical practice rather than from controlled dose-optimization trials.
CJC-1295
In Phase I/II trials, CJC-1295 with DAC was given as a subcutaneous injection once or twice per week. The DAC modification (drug affinity complex) extends the active window to several days, which is what allows the once-or-twice-weekly schedule rather than daily injection.
How strong
MK-677
The oral GH secretagogue. Multiple short-term controlled studies (8 weeks to 6 months) demonstrate GH and IGF-1 elevation, body composition effects, bone turnover markers, and sleep quality improvements (Copinschi 1997 showed 50% increase in stage 4 sleep duration). Reversed diet-induced catabolism in healthy volunteers (Murphy 1998). Fat-free mass gains in obese men (Svensson 1998).
Ipamorelin
Moderate GH elevation with the cleanest hormonal profile in the secretagogue class. The GH pulse follows the body's natural pulsatile pattern rather than producing sustained elevation. The selectivity advantage is the pharmacological identity of the molecule.
CJC-1295
Stronger and more sustained. A bigger growth hormone pulse that lasts longer.
Main tradeoff
MK-677
Oral convenience versus metabolic side effects is the core trade-off. MK-677 raises appetite (ghrelin is the hunger hormone), may elevate blood glucose and reduce insulin sensitivity, and causes water retention. The 24-week Murphy 2008 elderly hip-fracture study was discontinued due to a congestive heart failure signal in that population, the most concerning safety finding in the published literature. Whether the elderly CHF signal applies to healthy younger populations is not established. The compound has not passed Phase III trials despite decades of investigation. Compared to ipamorelin (the selective injectable alternative), MK-677 lacks the clean hormonal selectivity profile.
Ipamorelin
The selectivity that makes ipamorelin distinctive is well documented, but clinical outcome data beyond the single Phase II post-surgical GI trial (Beck 2014) is absent. One of the most widely used peptides in clinical practice has almost no published outcomes data for the endpoints practitioners actually prescribe it for. The CJC-1295 plus ipamorelin combination has never been tested in a controlled comparison study despite being the most common clinical protocol.
CJC-1295
Less pulsatile than the body's natural rhythm. Side effects, if they happen, stick around longer because the drug stays active longer.
Best for
MK-677
- Research interest in oral GH secretagogue mechanisms compared to injectable alternatives
- Research comparing sustained GH elevation (MK-677) versus pulsatile release (ipamorelin, sermorelin)
- Research contexts where the oral-versus-injectable administration question is central
Ipamorelin
- Research interest in selective GH secretagogues with minimal off-target hormonal effects
- Research comparing GH secretagogue selectivity profiles across the class
- Research contexts where the CJC-1295 plus ipamorelin pairing is the protocol under study
CJC-1295
- People who want fewer injections per week
- People who've plateaued on Sermorelin
- Anyone planning to stack with Ipamorelin (a popular combination because the two work through different receptors and amplify each other)
How to choose
A good fit for MK-677
- Research prioritizing oral administration (injection avoidance)
- Research comparing sustained GH elevation versus pulsatile release patterns
- Research contexts where the longest published human trial data matters (MK-677 has multi-month studies)
A good fit for Ipamorelin
- Research prioritizing hormonal selectivity (zero cortisol, zero prolactin, zero ACTH changes)
- Research comparing GH secretagogue selectivity profiles across the class
- Research contexts where the CJC-1295 plus ipamorelin pairing is the protocol under study
A good fit for CJC-1295
- Research prioritizing fewer injection frequency (once or twice weekly vs daily)
- Research comparing GHRH receptor activation versus ghrelin receptor activation for GH release
- Research contexts where sustained multi-day GH elevation is the pharmacokinetic goal
Consider all three
MK-677, ipamorelin, and CJC-1295 all elevate growth hormone but through different pathways and with different trade-offs. MK-677 and ipamorelin both activate the ghrelin receptor (GHS-R1a), but MK-677 is oral with metabolic side effects while ipamorelin is injectable with clean selectivity. CJC-1295 activates the GHRH receptor instead, producing sustained GH elevation over days. Ipamorelin and CJC-1295 are the most commonly paired combination in clinical protocols because they work through complementary receptors. For pairwise comparisons: MK-677 vs HGH (oral secretagogue vs direct hormone replacement), Sermorelin vs CJC-1295 (daily vs weekly GHRH analogs).
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Ghrelin Receptor (GHS-R1a)
- Ghrelin Receptor (GHS-R1a) activates Pituitary Somatotrophs
- Pituitary Somatotrophs connects to Growth Hormone Release
- Growth Hormone Release stimulates Liver IGF-1 Production
- Liver IGF-1 Production connects to IGF-1 Elevation; Growth Hormone Release connects to IGF-1 Elevation
- GHS-R1a Receptor
- GHS-R1a Receptor activates Ghrelin Mimicry
- Ghrelin Mimicry connects to Anterior Pituitary
- Anterior Pituitary connects to Growth Hormone Release
MK-677 binds the ghrelin receptor (GHS-R1a) on the pituitary gland to trigger growth hormone release; in pill form.
Ipamorelin selectively binds the ghrelin receptor on pituitary somatotrophs to trigger growth hormone release without raising cortisol or prolactin.
CJC-1295 mimics GHRH to tell the pituitary gland to release growth hormone; the DAC modification extends activity from minutes to days.
Research Evidence
MK-677 has the deepest human trial data in this trio: multiple controlled studies spanning 8 to 24 weeks demonstrating GH and IGF-1 elevation, body composition effects, bone turnover markers, and sleep quality improvements. The 24-week elderly hip-fracture study (Murphy 2008) was discontinued due to a congestive heart failure signal. Ipamorelin has 48 published studies with human pharmacodynamic data confirming the selectivity profile (Raun 1998, Johansen 1999) and a single Phase II post-surgical trial (Beck 2014). CJC-1295 has approximately 27 studies, mostly pharmacokinetic data characterizing sustained GH release. None has completed Phase III trials or received FDA approval.
- 1.
If oral delivery is important for the research model or clinical context, MK-677 is the only orally active compound among these three, but appetite stimulation and insulin resistance must be accounted for.
- 2.
If selectivity for GH release with minimal cortisol and prolactin effects is the priority, ipamorelin has the strongest selectivity data among GHRPs, though its overall evidence base is limited.
- 3.
If sustained GH/IGF-1 elevation with infrequent dosing is desired, CJC-1295 with DAC offers multi-day effects from a single injection, though sustained elevation carries theoretical safety considerations.
- 4.
If the research question involves GH axis physiology, combining a GHRH analog (CJC-1295) with a GHRP (ipamorelin) has theoretical rationale for synergistic stimulation, though combination data is limited.
Key Limitations
- •None of these compounds is FDA-approved, all evidence is from research or early clinical studies.
- •MK-677's effects on insulin resistance and appetite may limit its utility in metabolic contexts where these are concerns.
- •Ipamorelin's selectivity advantage is based on comparisons with other GHRPs, not on comprehensive standalone clinical validation.
- •CJC-1295 development was discontinued before Phase III, leaving efficacy questions unresolved.
- •The clinical significance of different GH stimulation patterns (ghrelin-mediated vs. GHRH-mediated) is not fully established.
- •Combination protocols (e.g., ipamorelin + CJC-1295) are widely discussed but minimally studied in formal research settings.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
MK-677
"MK-677 increased my growth hormone levels significantly"
Supported by published data
"It made me hungry all the time and I gained fat"
Supported by published data
"I use it for better sleep and recovery"
Plausible but unproven
Ipamorelin
"Ipamorelin is the cleanest GH secretagogue with the fewest side effects"
Plausible but unproven
"Combined with CJC-1295 it mimics natural GH pulsing"
Plausible but unproven
"It helped with my joint pain and recovery"
Anecdotal only
CJC-1295
"CJC-1295 with DAC gives you sustained growth hormone elevation for days"
Supported by published data
"Stacking CJC-1295 with ipamorelin is the gold standard for GH optimization"
Plausible but unproven
"It made me retain water and feel bloated"
Supported by published data
Safety Comparison
MK-677's safety profile includes increased appetite, potential blood glucose elevation, water retention, and the elderly hip-fracture CHF signal requiring monitoring. Ipamorelin has the cleanest safety profile in the trio: no cortisol, prolactin, or ACTH changes at GH-stimulating doses. CJC-1295 side effects include water retention, numbness, and injection site reactions. None is FDA-approved. None has long-term human safety data. Compounded versions sold in research-peptide markets are not FDA-regulated.
MK-677
Human trials up to 2 years have been conducted. Common effects include increased appetite, transient edema, and mild increases in fasting glucose and insulin resistance. Effects on cortisol and prolactin are generally modest but measurable. Long-term metabolic effects of sustained GH/IGF-1 elevation require further study.
Ipamorelin
Limited human safety data. Preclinical and early clinical studies suggest a favorable selectivity profile with minimal cortisol or prolactin elevation. However, the overall safety dataset is thin compared to MK-677 or sermorelin. Injectable delivery introduces standard injection-site considerations.
CJC-1295
Phase I/II data exists for both variants. The DAC variant's sustained GH elevation raises theoretical concerns about prolonged IGF-1 exposure. Without DAC, the pharmacokinetic profile is closer to endogenous GHRH. Injection-site reactions reported. Overall human safety dataset is limited in size.
What the Research Suggests
These three compounds represent three distinct approaches to GH secretagogue research: oral ghrelin mimicry (MK-677), selective peptide-based ghrelin receptor activation (ipamorelin), and GHRH pathway stimulation (CJC-1295). MK-677 has the strongest evidence base (Human Trials) but the broadest side-effect profile. Ipamorelin and CJC-1295 are both PSI Animal Studies: ipamorelin for a small selective GHRP literature; CJC-1295 for PK-focused Phase I/II work without Phase III. CJC-1295's DAC variant remains distinctive for duration of action. The choice depends on delivery route, hormonal selectivity, duration of action, and side-effect trade-offs. None should be considered clinically validated for therapeutic use.